Nordson is a quality precision-machinery compounder. Its Q2 FY26 was a record quarter — sales $741M (+8%), adjusted EPS $2.86 (+18%) — and management raised full-year guidance, extending a clean earnings run (three beats plus one in-line)SEC 8-K· mai 2026. The chart shows the tightest, least-extended setup of the quality-industrial group — EMA20 > EMA50 > EMA200 neatly stacked, RSI a calm 54, price just 1.3% above EMA20 and ~6% below its 52-week high. The catch: a balance-sheet-clean Dividend King at 24x forward is fairly — not cheaply — priced, and TP1 sits right at the prior peak.
Nordson Corporation engineers precision dispensing, fluid-management, and test-and-inspection systems — the unglamorous but mission-critical equipment that lays down adhesives, sealants, coatings and biomaterials, and verifies that electronics and medical devices are built right. The company sells into deeply embedded niches where its installed base, consumables and service create a recurring, sticky revenue streamStockAnalysis· juin 2026.
The business runs across three segments: Industrial Precision Solutions (adhesive dispensing, packaging, polymer processing), Medical and Fluid Solutions (medical components, single-use plastics, biomaterials), and Advanced Technology Solutions (electronics test, inspection and precision dispensing for semis and PCBs). The moat is razor/razor-blade economics plus engineering specificity: once a Nordson dispense head is qualified on a customer's line, switching is costly and rare. That is what funds a 55% gross margin, a 23.5% operating margin and a 62-year dividend-raise streak — Nordson is a bona-fide Dividend KingYahoo Finance· profile.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $2.90B | +8% YoY (Q2) |
| EBITDA (TTM) | $911M | ~31% margin |
| Net Income (TTM) | $528M | Growing |
| Gross Margin | 55.2% | Excellent |
| Operating Margin | 23.5% | Strong |
| Net Margin | 18.2% | Healthy |
| ROE | 16.9% | Solid |
| Debt / Equity | 0.62 | Investment-grade |
| Current Ratio | 2.60 | Liquid |
| P/E (trailing) | 30.8x | Quality premium |
| Fwd P/E | 24.2x | Fair |
| Analyst Target | $310 – $319 | +8–11% upside |
This is a high-quality machine. A 55% gross margin and 23.5% operating margin on $2.9B of revenue, financed with a conservative 0.62 debt/equity and a 2.6 current ratio, is the financial signature of a wide-moat compounder. FY25 EBITDA margin printed ~31%, and the TTM is holding ~31%StockAnalysis· juin 2026. The valuation — 24x forward — is the honest caveat: this is a fair price for quality, not a bargain. The Street consensus sits at $310–$319, an 8–11% premium to spot, with a high estimate of $335StockAnalysis Forecast· juin 2026.
| Price | $288.21 |
| RSI (14) | 54.2 |
| EMA 20 | $284.46 |
| EMA 50 | $281.43 |
| EMA 200 | $261.75 |
| ATR (14) | $6.61 (2.3%) |
| Extension vs EMA20 | +1.32% |
| 52W High | $305.28 |
Textbook bullish structure with minimal extension. EMA20 ($284.46) > EMA50 ($281.43) > EMA200 ($261.75) — a clean, upward-sloping stack with price riding just 1.3% above the EMA20Yahoo Finance· live. RSI at 54.2 sits in the calm middle of the range — there is no overbought condition to unwind, which is exactly what you want before a breakout attempt. ATR of $6.61 (2.3%) is low, giving precise risk control. The whole thesis funnels into one level: $305.28, the 52-week high. A daily close above it on volume opens clean air toward $322.50 (1.382 Fibonacci extension of the EMA200-to-high range); failure there is the natural place to step aside.
EDGAR shows no active equity dilution programs for Nordson: no equity ATM, no convertible notes, no mandatory-convertible preferreds, and no 424B5 equity offerings. A 2023 S-3ASR shelf registration is on file — as standard for a well-known seasoned issuer, it technically covers debt and equity securities, but every prospectus supplement filed under it (424B2 in 2023 and 2024) has been for senior-note debt issuances onlySEC EDGAR· 2023–24. Share count is stable at ~55.7M; stock-based compensation (~$48M/yr) creates mild dilution that is more than offset by the $500M buyback authorization approved in Q3 FY25StockAnalysis· juin 2026.
A wide-moat, balance-sheet-clean compounder with a 62-year dividend streak. The real risks are valuation (fair, not cheap), a TP1 that sits at resistance, and late-cycle capex sensitivity — not balance-sheet or dilution risk.
Nordson's risk is almost entirely about price paid, not business quality. There is no dilution, no toxic financing, no cash-burn problem, and no leverage stress — the balance sheet is investment-grade. The two risks that actually matter are valuation (24x leaves little cushion for a miss) and the chart (TP1 sits at resistance). Both are managed by the trade plan below: a tight stop under the EMA structure and scaling out into the 52-week highStockAnalysis· juin 2026.
Buy a quality compounder on the cleanest setup of the group. A record Q2, a guidance raise to $11.30–$11.80 EPS, and a streak of three beats plus one in-line give the fundamentals momentum, while the chart offers a low-extension entry with EMAs neatly stacked. The math: from a $286.80 limit entry, risk to the $274.90 stop is $11.90; reward to the $304.80 TP1 is $18.00 — a 1.5 R/R [ (304.80 − 286.80) ÷ (286.80 − 274.90) = 1.51 ]. On a confirmed breakout above the 52-week high, TP2 at $322.50 stretches the reward to 3.0 R/R.
Horizon: swing (2–8 weeks). Scale out into TP1 at the 52-week high; trail the remainder only on a confirmed daily close above $305.28.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
The trade levels shown (entry, stop, targets) are illustrative and not personalized to your financial situation, objectives, or risk tolerance. DailyTickers and its authors hold no position in NDSN at the time of publication and receive no compensation from Nordson Corporation; this analysis is independent and not sponsored.
Data sourced from Yahoo Finance, StockAnalysis.com, and SEC EDGAR (CIK 0000072331), verified as of 14 juin 2026. Accuracy is not guaranteed.